For the first time ever, Glaucoma UK has 12 charity places in the iconic TCS London Marathon for 2026, and applications are now officially open! Mark your calendars - the big day is Sunday 26 April 2026! In previous years,...
The Association of British Dispensing Opticians (ABDO) has launched an updated ABDO CPD Child Safeguarding Level 2 course this month, accredited by Ofqual. The qualification is designed to enhance professionals’ understanding and implementation of child safeguarding practices within the optical...
New dates. New location. Same unmissable experience. SightCare is delighted to announce that SightCare LIVE 2026 – the flagship conference, awards and exhibition – will take place on Sunday 26 and Monday 27 April 2026 at an exciting new venue:...
This is a randomised trial of patients recruited between the periods of March 2006 and March 2008 from ophthalmology clinics in the Leicestershire area. A total of 62 children with newly diagnosed amblyopia were allocated randomly into two treatment arms...
This is a prospective study from a single unit to compare the visual outcome of aspheric toric intraocular lens (IOL) implantation and limbal relaxing incisions (LRI) for management of coexisting age-related cataracts and astigmatism. Sixty eyes of 60 patients with...
“Is it a fact – or have I dreamt it – that, by means of electricity, the world of matter has become a great nerve, vibrating thousands of miles in a breathless point of time?” – Nathaniel Hawthorne, The House...
Central retinal vein occlusion (CRVO) is the second most common retinal vascular disease after diabetic retinopathy, and its clinical complexity often intersects with medico-legal scrutiny [1]. Missteps in timely diagnosis, inadequate follow-up or poor documentation can lead to patient harm...
Completion of Core Training is approaching fast and you begin to wonder three things. One, where do you want to live? Two, is anyone going to be retiring there soon? Three, what subspecialty do you want to do? In an...
Gene and cell therapies offer the prospect of ground-breaking new avenues for the treatment of diseases, reflected in a renewed explosion of interest and investment in retinal gene therapy. Rod McNeil reports recent clinical trial readouts across a diverse range...